Does Kaiser Permanente Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?

Why Kaiser Permanente Does Not Cover NMN or NR

Kaiser Permanente operates a closed formulary, meaning only drugs reviewed and approved by its Pharmacy and Therapeutics Committee appear on its coverage list. NMN and NR are NAD+ precursors sold as dietary supplements, not FDA-approved pharmaceuticals. No U.S. health insurer, Kaiser included, lists either compound on a standard formulary [1].

The reason is structural, not a coverage gap that prior authorization can bridge. Kaiser's internal pharmacy system requires an FDA-assigned National Drug Code (NDC) tied to an approved New Drug Application (NDA) or Abbreviated NDA. Supplements lack these designations. Even if a Kaiser-employed physician wanted to prescribe NMN or NR for a specific clinical indication, the pharmacy system has no monograph to dispense against. This is a different situation from, say, an off-formulary branded drug where a physician can request an exception. There is no drug product to make an exception for.

The distinction matters for members who read about NAD+ precursors in longevity-medicine contexts and assume insurance should cover them. Coverage requires regulatory approval first. That approval does not exist for either molecule as of mid-2026.

The Regulatory Split Between NMN and NR

NMN and NR are often discussed together, but their legal statuses diverged sharply in late 2022. The FDA issued a determination that NMN could not be marketed as a dietary supplement because it was being investigated as a new drug by Metro International Biotech (now part of the research pipeline exploring NAD+ biology) [2]. This meant retailers had to pull NMN products from shelves, though enforcement has been inconsistent.

NR, by contrast, received FDA "New Dietary Ingredient" notification acceptance years earlier. Chromadex's Tru Niagen (nicotinamide riboside chloride) remains legally sold as a supplement. It carries no FDA drug approval, but it can be manufactured and sold under the Dietary Supplement Health and Education Act (DSHEA) framework [3].

This regulatory split has practical consequences for anyone trying to get insurance coverage. NR is a legal supplement with no path to formulary listing. NMN is in regulatory limbo with a theoretical path to drug approval if a pharmaceutical sponsor completes clinical trials and files an NDA. If NMN ever receives FDA approval as a prescription drug, insurers including Kaiser would then evaluate it for formulary inclusion. That timeline, if it happens at all, likely stretches years into the future.

What the Clinical Evidence Actually Shows

The most cited human trial for NMN is Yoshino et al., published in Science in 2021. This 10-week randomized controlled trial enrolled 25 postmenopausal women with prediabetes and obesity, giving them 250 mg/day of NMN or placebo. NMN supplementation improved skeletal muscle insulin sensitivity by approximately 25% as measured by hyperinsulinemic-euglycemic clamp. No significant changes in body weight, blood pressure, or plasma lipids were observed [4].

That trial was small. Twenty-five participants over 10 weeks cannot establish the kind of evidence base that FDA approval or insurer coverage requires. For comparison, the STEP-1 trial that supported semaglutide's obesity indication enrolled 1,961 participants over 68 weeks [5].

For NR, a 2018 randomized crossover trial by Martens et al. in Nature Communications found that 6 weeks of NR supplementation (1 to 000 mg/day) in 24 healthy middle-aged and older adults reduced systolic blood pressure by a mean of 5.1 mmHg and reduced aortic stiffness [6]. Again, the sample was tiny. A systematic review published in the Journal of Clinical Endocrinology & Metabolism in 2023 pooled data across NR and NMN trials and concluded that while both compounds reliably increase blood NAD+ levels, evidence for clinically meaningful endpoints remains "insufficient for clinical recommendations" [7].

Dr. Charles Brenner, the biochemist who discovered NR's role as an NAD+ precursor, has stated publicly: "NAD+ precursors raise NAD. The question is whether raising NAD translates to the outcomes people care about. We need larger, longer trials to answer that." That candor from the scientist most associated with NR research underscores why no regulatory body has approved these compounds as treatments for any condition.

Prior Authorization and Step Therapy: Why They Don't Apply

Kaiser Permanente's prior authorization process exists for drugs that are on the formulary but restricted to specific clinical criteria. Step therapy requires trying a first-line agent before a more expensive alternative. Neither mechanism applies to NMN or NR because neither compound appears in Kaiser's drug database at all.

Some members confuse this with a coverage denial. It is not. A denial implies the drug was evaluated and rejected for that specific patient. With NMN and NR, there is nothing to evaluate. The system has no entry for these molecules. If you call Kaiser Member Services and ask about NMN coverage, the representative will not find a prior authorization form or step therapy protocol. They will find no listing whatsoever.

This distinction also affects appeal rights. Kaiser members can appeal a denied claim through internal review and then to their state's Independent Review Organization (IRO). But an appeal requires an initial coverage determination to appeal against. When the drug simply does not exist in the formulary system, there is no determination to challenge. Some members have attempted to frame this as a "constructive denial," but state IRO panels have consistently held that supplements without FDA drug approval fall outside the scope of mandated coverage review [8].

What NMN and NR Actually Cost Out of Pocket

Because insurance coverage is off the table, the relevant question for most people is cash price. Here the numbers are relatively modest compared to prescription longevity-adjacent drugs.

NR (as Tru Niagen, 300 mg/day) retails for approximately $40 to $50 per month through the manufacturer's website and major retailers. Higher doses (up to 1 to 000 mg/day, matching the Martens et al. protocol) cost $80 to $120 per month. Generic NR products from other supplement companies may be cheaper, though third-party purity testing varies [3].

NMN pricing is harder to pin down given the regulatory uncertainty. Products sold through online retailers (some of questionable legal compliance) range from $30 to $100 per month for 250 to 500 mg/day. Quality control is a real concern. A 2022 analysis found that several NMN products contained less than 50% of the labeled dose, while others contained contaminants [9].

Neither compound qualifies for Health Savings Account (HSA) or Flexible Spending Account (FSA) reimbursement under standard IRS rules, because they are not prescribed to treat a diagnosed medical condition. Some longevity-medicine clinics write prescriptions for compounded NMN through 503B pharmacies, which may change the FSA/HSA calculus for individual members, but Kaiser does not participate in this model.

Could Kaiser Ever Cover NAD+ Precursors?

The path to Kaiser formulary inclusion follows a predictable sequence. First, a pharmaceutical company must complete Phase III trials demonstrating safety and efficacy for a specific indication. Second, the FDA must approve the resulting NDA. Third, Kaiser's Pharmacy and Therapeutics Committee must review the drug and assign a formulary tier.

Metro International Biotech (MIB-626, an NMN formulation) had early-stage clinical data suggesting improvements in physical performance metrics in older adults, but no Phase III program has been publicly announced as of mid-2026 [10]. If MIB-626 or a similar NMN product reaches FDA approval, the timeline from approval to Kaiser formulary listing typically runs 6 to 18 months, depending on the therapeutic category and cost.

For NR, no pharmaceutical sponsor has announced plans to pursue FDA drug approval. ChromaDex has positioned Tru Niagen as a supplement, not a drug candidate. Without a sponsor willing to invest in Phase III trials (estimated cost: $50 to $200 million), NR will remain a supplement indefinitely.

The Endocrine Society's 2024 position statement on NAD+ metabolism noted that "while preclinical data are provocative, the translational gap between animal models showing lifespan extension and human clinical outcomes remains substantial" [11]. Until that gap closes with large randomized controlled trials, regulatory and insurance coverage will not follow.

What to Do if Your Doctor Recommends NMN or NR

If a physician (inside or outside Kaiser's network) recommends an NAD+ precursor, the practical steps are straightforward. Purchase the supplement out of pocket. Choose a product that carries USP, NSF International, or ConsumerLab verification. Start with the doses used in published trials (250 mg/day for NMN per Yoshino et al.; 300 to 1 to 000 mg/day for NR per Martens et al.). Monitor baseline and follow-up NAD+ levels if your provider offers this testing, though the clinical utility of tracking serum NAD+ is itself unproven.

Do not expect Kaiser to reimburse you retroactively. Do not file a claim expecting a denial you can appeal. The system is simply not built to process supplements as covered benefits, regardless of the clinical rationale a provider may offer.

If you are a Kaiser member interested in evidence-based longevity interventions that are covered, ask your primary care physician about blood pressure management, statin therapy for qualifying cardiovascular risk, diabetes prevention programs, and cancer screening. These carry decades of randomized trial data and are fully integrated into Kaiser's preventive care model [12].

How Kaiser's Model Differs from PPO Plans on Supplement Access

Kaiser's integrated HMO model means your physician, pharmacy, and insurer are part of the same organization. There is no out-of-network pharmacy benefit and no mechanism to submit a claim for a product purchased at an outside retailer. PPO plans, by contrast, sometimes allow members to submit out-of-network pharmacy claims for medications purchased at non-network pharmacies. Even in PPO plans, supplements are excluded, but the claims pathway at least exists as a theoretical entry point.

Kaiser members sometimes ask whether switching to a PPO plan at open enrollment would give them supplement coverage. It would not. No commercial health plan in the United States covers NMN or NR. The only scenario where an insurer might cover an NAD+ precursor is if a physician prescribes a compounded formulation for a specific off-label medical indication and the plan has a compounding benefit. This is rare, plan-specific, and would not apply to Kaiser's structure.

The monthly cost difference between Kaiser HMO and a comparable PPO plan in most markets ranges from $100 to $300. Switching plans solely to pursue supplement reimbursement that does not exist would increase costs without any offsetting benefit.